Pharmaceutical Era

Search your requirement

  • Home
  • Press Releases
    • Submit Release
  • Events
  • Reach Us

Social media

Pharmaceutical Era Pharmaceutical Era
  • Home
  • Press Releases
    • Submit Release
  • Events
  • Reach Us
MilliporeSigma receives the industry
MilliporeSigma receives the industry's first EXCiPACT certification for cell culture media manufacturing
Ibex Medical Analytics achieves notable milestones with its AI-first approach to cancer diagnostics
Ibex Medical Analytics achieves notable milestones with its AI-first approach to cancer diagnostics
Albertsons Companies pharmacies now offer COVID and flu vaccines to help protect communities this respiratory virus season
Albertsons Companies pharmacies now offer COVID and flu vaccines to help protect communities this respiratory virus season
OmniSYS rebrands as XiFin Pharmacy Solutions, launches Pharmacy Payor Rate Transparency Monitor, and earns the Pharmacy 500 Award
OmniSYS rebrands as XiFin Pharmacy Solutions, launches Pharmacy Payor Rate Transparency Monitor, and earns the Pharmacy 500 Award
Gilead’s Livdelzi (Seladelpar) receives FDA accelerated approval for primary biliary cholangitis
Gilead’s Livdelzi (Seladelpar) receives FDA accelerated approval for primary biliary cholangitis
ProJenX announces the formation of its Clinical Advisory Board
ProJenX announces the formation of its Clinical Advisory Board
Citius Pharmaceuticals
Citius Pharmaceuticals' LYMPHIR™ wins FDA approval for relapsed/refractory cutaneous T-cell lymphoma
NewAmsterdam Pharma announces positive topline data from the Phase 3 BROOKLYN trial of Obicetrapib in heterozygous familial hypercholesterolemia patients
NewAmsterdam Pharma announces positive topline data from the Phase 3 BROOKLYN trial of Obicetrapib in heterozygous familial hypercholesterolemia patients
Cygnus Technologies and TriLink BioTechnologies® collaborate to launch AccuRes™ Host Cell DNA Quantification Kits
Cygnus Technologies and TriLink BioTechnologies® collaborate to launch AccuRes™ Host Cell DNA Quantification Kits
Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules.
Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules.
Updated flu and COVID-19 vaccinations are now available at CVS Pharmacy® and MinuteClinic
Updated flu and COVID-19 vaccinations are now available at CVS Pharmacy® and MinuteClinic
FDA Grants Second Approval for EPKINLY® (epcoritamab-bysp) to Treat Relapsed or Refractory Follicular Lymphoma
FDA Grants Second Approval for EPKINLY® (epcoritamab-bysp) to Treat Relapsed or Refractory Follicular Lymphoma

Featured Press Releases

Alamar Biosciences Launches NULISAqpcr™ BD-pTau217 Assay: A Breakthrough in Non-Invasive Alzheimer’s Biomarker Detection

Alamar Biosciences Launches NULISAqpcr™ BD-pTau217 Assay: A Breakthrough in Non-Invasive Alzheimer’s Biomarker Detection

  • By Alamar Biosciences
  • Alamar Biosciences
  • 14 Oct 2025
FDA Approves ZOLL’s Zenix Monitor/Defibrillator, Elevating Asahi Kasei’s Critical Care Solutions

FDA Approves ZOLL’s Zenix Monitor/Defibrillator, Elevating Asahi Kasei’s Critical Care Solutions

  • By Asahi Kasei Corp.
  • Asahi Kasei Corp.
  • 13 Oct 2025
Shanchol® Oral Cholera Vaccine Prequalified by WHO, Ensuring Continuity of Global Supply

Shanchol® Oral Cholera Vaccine Prequalified by WHO, Ensuring Continuity of Global Supply

  • By Shantha GCBC Vaccines
  • Shantha GCBC Vaccines
  • 13 Oct 2025
Pharmaceutical Leader Nia Tatsis, Ph.D., Appointed to Odyssey Therapeutics’ Board of Directors

Pharmaceutical Leader Nia Tatsis, Ph.D., Appointed to Odyssey Therapeutics’ Board of Directors

  • By Odyssey Therapeutics, Inc.
  • Odyssey Therapeutics, Inc.
  • 13 Oct 2025
Dr. Zivjena Vucetic Appointed as Chief Medical Officer at Mission Bio to Lead Biopharma Partnerships and Clinical Adoption

Dr. Zivjena Vucetic Appointed as Chief Medical Officer at Mission Bio to Lead Biopharma Partnerships and Clinical Adoption

  • By Mission Bio
  • Mission Bio
  • 09 Oct 2025
Therapeutics Complement Receives FDA IND Clearance to Advance CTx001 into Opti-GAIN, a Phase I/II Clinical Trial in Geographic Atrophy Secondary to AMD

Therapeutics Complement Receives FDA IND Clearance to Advance CTx001 into Opti-GAIN, a Phase I/II Clinical Trial in Geographic Atrophy Secondary to AMD

  • By Complement Therapeutics
  • Complement Therapeutics
  • 08 Oct 2025
Log in
Show
  • Create an account
  • Forgot your username?
  • Forgot your password?
World Drug Delivery Summit 2025
The Digital Pharma Advances Conference 2026

Most Popular

  • Lunit joins Roche
    Lunit joins Roche's Digital Pathology Open Environment to advance cancer biomarker testing
    By Lunit
    Sep 09
  • IKA introduces new accessories for the HABITAT research bioreactor.
    IKA introduces new accessories for the HABITAT research bioreactor.
    By IKA Werke GmbH & Co KG
    Sep 05
  • Hyalex Orthopaedics Reports Treatment of First Patients with Novel HYALEX® Knee Cartilage System
    Hyalex Orthopaedics Reports Treatment of First Patients with Novel HYALEX® Knee Cartilage System
    By Hyalex Orthopaedics
    Apr 23
January   2026
M T W T F S S
      1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31  

User Area

  • Login page
  • Registration
  • Edit Profile
  • Forgot Password

Discover

  • About Us
  • Terms Of Use
  • Privacy Policy
  • FAQs

Engage with Us

  • Search on Site
  • Post Press Release
  • Promote Brand
  • List Your Event

Subscribe for e-Newsletter Monthly

Subscribe to the Pharmaceutical Era newsletter to receive timely updates from your favorite products.
loader
Antispam refresh
© Pharmaceutical Era — A product of HISSM. All Rights Reserved.
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. To find out more, please click here.